IGIV-C

DRUG4 trials

Sponsors

Grifols Therapeutics LLC, Beth Israel Deaconess Medical Center

Conditions

Diabetes ComplicationsDiabetes MellitusDiabetic NeuropathiesMyasthenia GravisMyasthenia Gravis ExacerbationsMyasthenia Gravis, Generalized

Phase 2

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

CompletedNCT02473952

Grifols Therapeutics LLCMyasthenia Gravis, Generalized

Start: 2015-08-31End: 2018-01-31Updated: 2019-03-05

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

CompletedNCT02473965

Grifols Therapeutics LLCMyasthenia Gravis

Start: 2015-06-30End: 2019-02-28Updated: 2020-03-30

The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

TerminatedNCT02915263

Beth Israel Deaconess Medical CenterDiabetes Complications, Diabetes Mellitus, Diabetic Neuropathies

Start: 2017-09-11End: 2022-02-01Updated: 2024-05-07

Phase 3

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

CompletedNCT02413580

Grifols Therapeutics LLCMyasthenia Gravis Exacerbations

Start: 2015-03-31End: 2018-04-30Updated: 2020-04-24

Related Papers

Numbers Needed to Treat and Costs Per Improved Outcome Among Treatments for Myasthenia Gravis

Neurology2022-12-05

Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.

2022-10-2117 citations